Department of Anesthesiology, Baoding No.2 central hospital, Zhuozhou, China.
Department of Anesthesiology, Shanxi Bethune hospital, Taiyuan, China.
Ann Noninvasive Electrocardiol. 2023 May;28(3):e13050. doi: 10.1111/anec.13050. Epub 2023 Feb 6.
This study aimed to investigate the efficacy and safety of extrapleural block (EPB) application in patients with coronary artery disease after thoracoscopic surgery.
Patients with typical symptoms of angina and myocardial ischemia who underwent thoracoscopic surgery at our institution between December 2018 and December 2020 were screened for eligibility and they received paravertebral blocking (PVB), EPB, and patient-controlled intravenous analgesia (PCIA). Visual analog scale (VAS) scores were used to assess the analgesic effect and safety outcomes included heart rate, incidence of postoperative rescue analgesics, cardiac complications, and adverse reactions such as nausea and vomiting.
In total, 76 patients (age: 66.5 [61.3, 71] years; male: 63.2%) were eligible, including the PVB group (n = 22), EPB group (n = 25), and PVIA group (n = 29) with comparable baseline characteristics. There was a significantly higher proportion of patients with a VAS score of 1 in the EPB group compared with the other groups at 4 h (88.0% vs. 10.3% for PCIA and 45.5% for PVB; p < .001) and 6 h after the surgery (32.0% vs. 3.4% for PCIA and 13.6% for PVB; p = .012). The preoperative heart rate in the EPB group (81 [71, 94] beats/min) was slightly higher than those in the PVB (76 [70, 85] beats/min) and PCIA groups (76 [69, 84 beats/min]) but without significant difference (p = .193). There was no significant difference in the incidence of rescue analgesia, adverse events, and cardiac complications among the three groups (p = .296, .808, and .669, respectively.) CONCLUSION: Compared with PVB and PCIA, the EPB could more effectively relieve acute pain after thoracoscopic surgery in patients with coronary artery disease and offer comparable safety benefits in the management of postoperative heart rate, adverse events, and cardiac complications.
本研究旨在探讨胸腔镜手术后应用胸膜外阻滞(EPB)对冠心病患者的疗效和安全性。
本研究筛选了 2018 年 12 月至 2020 年 12 月在我院行胸腔镜手术且有典型心绞痛和心肌缺血症状的患者,将其纳入研究并接受椎旁阻滞(PVB)、EPB 和患者自控静脉镇痛(PCIA)。采用视觉模拟评分(VAS)评估镇痛效果,安全性结局包括心率、术后补救性镇痛药物的使用情况、心脏并发症和恶心呕吐等不良反应。
共纳入 76 例患者(年龄:66.5[61.3,71]岁;男性:63.2%),其中 PVB 组(n=22)、EPB 组(n=25)和 PCIA 组(n=29)的基线特征相似。EPB 组术后 4 小时(88.0%比 PCIA 组的 10.3%和 PVB 组的 45.5%,p<0.001)和 6 小时(32.0%比 PCIA 组的 3.4%和 PVB 组的 13.6%,p=0.012)VAS 评分 1 的患者比例明显更高。EPB 组术前心率(81[71,94]次/分)略高于 PVB 组(76[70,85]次/分)和 PCIA 组(76[69,84]次/分),但差异无统计学意义(p=0.193)。三组间补救性镇痛药物的使用、不良反应和心脏并发症的发生率差异均无统计学意义(p=0.296、0.808 和 0.669)。
与 PVB 和 PCIA 相比,EPB 可更有效地缓解冠心病患者胸腔镜手术后的急性疼痛,在管理术后心率、不良反应和心脏并发症方面具有相似的安全性。